PMID- 23307255
OWN - NLM
STAT- MEDLINE
DCOM- 20130725
LR  - 20211021
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 30
IP  - 1
DP  - 2013 Mar
TI  - Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic 
      patients with hepatocellular carcinoma.
PG  - 446
LID - 10.1007/s12032-012-0446-y [doi]
AB  - The incidence of hepatocellular carcinoma (HCC) is increasing worldwide and the 
      proportion of older patients with HCC is expected to steadily rise in the next 
      years. Sorafenib is the standard of care for patients with advanced HCC but there 
      is a lack of detailed data on how older patients with cirrhosis tolerate this 
      drug. Therefore, we aimed to evaluate the impact of age on the effects of 
      sorafenib-targeted therapy in patients with HCC and cirrhosis. We analyzed a 
      consecutive cohort of HCC patients not eligible for surgery or locoregional 
      treatment, with Child-Pugh score </= 7, and an Eastern Cooperative Oncology Group 
      performance status of 0-1, treated with sorafenib. Clinical outcomes and 
      treatment-related adverse events (AEs) were compared between younger (< 70 years) 
      and older (>/= 70 years) patients. Overall, 150 patients, 90 in the younger (median 
      age 60 years) and 60 in the older (median age 72 years) group, were evaluated. 
      Treatment duration was 4 months in both groups. The median time to progression 
      and overall survival were longer in older than in younger group (12 vs. 8 months 
      and 16 vs. 12 months, respectively), although the differences did not reach a 
      statistical significance. Grade 3-4 AEs were more frequently observed in younger 
      than in older group (15.7 vs. 9.2 %, respectively; p = .0146). In field practice, 
      sorafenib treatment in elderly patients with cirrhosis and HCC resulted at least 
      as effective and safe as in younger patients. However, severe AEs occurred more 
      frequently in younger patients.
FAU - Di Costanzo, Giovan Giuseppe
AU  - Di Costanzo GG
AD  - Liver Unit, Cardarelli Hospital, Via A. Cardarelli 9, 80131 Naples, Italy. 
      dicostanzogg@gmail.com
FAU - Tortora, Raffaella
AU  - Tortora R
FAU - De Luca, Massimo
AU  - De Luca M
FAU - Galeota Lanza, Alfonso
AU  - Galeota Lanza A
FAU - Lampasi, Filippo
AU  - Lampasi F
FAU - Tartaglione, Maria Teresa
AU  - Tartaglione MT
FAU - Picciotto, Francesco Paolo
AU  - Picciotto FP
FAU - Imparato, Michele
AU  - Imparato M
FAU - Mattera, Silvana
AU  - Mattera S
FAU - Cordone, Gabriella
AU  - Cordone G
FAU - Ascione, Antonio
AU  - Ascione A
LA  - eng
PT  - Journal Article
DEP - 20130110
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*adverse effects
MH  - Carcinoma, Hepatocellular/complications/*drug therapy/mortality
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Liver Cirrhosis/complications
MH  - Liver Neoplasms/complications/*drug therapy/mortality
MH  - Male
MH  - Middle Aged
MH  - Niacinamide/adverse effects/*analogs & derivatives
MH  - Phenylurea Compounds/*adverse effects
MH  - Sorafenib
EDAT- 2013/01/12 06:00
MHDA- 2013/07/26 06:00
CRDT- 2013/01/12 06:00
PHST- 2012/10/18 00:00 [received]
PHST- 2012/12/27 00:00 [accepted]
PHST- 2013/01/12 06:00 [entrez]
PHST- 2013/01/12 06:00 [pubmed]
PHST- 2013/07/26 06:00 [medline]
AID - 10.1007/s12032-012-0446-y [doi]
PST - ppublish
SO  - Med Oncol. 2013 Mar;30(1):446. doi: 10.1007/s12032-012-0446-y. Epub 2013 Jan 10.